JCR Pharmaceuticals Co., Ltd.(JP:4552)
Â¥493.00-11.00 (-2.18%)
JP:4552
JCR Pharmaceuticals Co., Ltd. financials statements
Â¥493.00
At close:-11.00 (-2.18%)
Want to see JP:4552 full AI Analyst Report?
JCR Pharmaceuticals Co., Ltd. (4552) Ratios
1 Followers
JCR Pharmaceuticals Co., Ltd. Ratios
JP:4552's free cash flow for Q3 2026 was ¥0.00. For the 2026 fiscal year, JP:4552's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.16 | 1.16 | 1.91 | 1.34 | 1.48 |
| Quick Ratio | 0.67 | 0.67 | 1.22 | 0.82 | 1.13 |
| Cash Ratio | 0.30 | 0.29 | 0.62 | 0.37 | 0.73 |
| Solvency Ratio | -0.02 | 0.08 | 0.19 | 0.14 | 0.36 |
| Operating Cash Flow Ratio | -0.12 | -0.00 | 0.31 | -0.15 | 0.22 |
| Short-Term Operating Cash Flow Coverage | -0.21 | -0.00 | 1.04 | -0.32 | 0.61 |
| Net Current Asset Value | ¥ -6.96B | ¥ -5.80B | ¥ 11.83B | ¥ 5.28B | ¥ 16.14B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.49 | 0.23 | 0.24 | 0.19 |
| Debt-to-Equity Ratio | 0.81 | 1.15 | 0.41 | 0.44 | 0.36 |
| Debt-to-Capital Ratio | 0.45 | 0.53 | 0.29 | 0.30 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.21 | 0.20 | 0.10 | 0.05 |
| Financial Leverage Ratio | 2.24 | 2.33 | 1.82 | 1.82 | 1.91 |
| Debt Service Coverage Ratio | -0.04 | 0.12 | 0.98 | 0.34 | 1.09 |
| Interest Coverage Ratio | -44.14 | 1.08 | 87.58 | 113.07 | 442.96 |
| Debt to Market Cap | 0.64 | 0.78 | 0.22 | 0.13 | 0.06 |
| Interest Debt Per Share | 310.44 | 445.21 | 187.40 | 183.77 | 146.66 |
| Net Debt to EBITDA | -8.70 | 6.45 | 0.43 | 1.28 | -0.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 65.15% | 74.56% | 72.90% | 74.13% | 79.52% |
| EBIT Margin | -18.93% | 8.98% | 17.10% | 15.89% | 38.07% |
| EBITDA Margin | -8.72% | 15.33% | 24.56% | 21.70% | 41.88% |
| Operating Profit Margin | -20.69% | 1.07% | 17.57% | 14.49% | 39.02% |
| Pretax Profit Margin | -19.39% | 8.00% | 16.90% | 15.76% | 37.99% |
| Net Profit Margin | -14.39% | 5.40% | 12.85% | 10.98% | 28.40% |
| Continuous Operations Profit Margin | -14.20% | 5.47% | 12.92% | 11.03% | 28.42% |
| Net Income Per EBT | 74.18% | 67.59% | 76.02% | 69.70% | 74.76% |
| EBT Per EBIT | 93.76% | 748.03% | 96.18% | 108.78% | 97.35% |
| Return on Assets (ROA) | -4.51% | 1.99% | 5.39% | 3.97% | 14.94% |
| Return on Equity (ROE) | -10.11% | 4.64% | 9.80% | 7.23% | 28.51% |
| Return on Capital Employed (ROCE) | -11.13% | 0.71% | 10.45% | 8.41% | 36.19% |
| Return on Invested Capital (ROIC) | -5.72% | 0.29% | 7.11% | 4.55% | 21.24% |
| Return on Tangible Assets | -4.64% | 2.04% | 5.58% | 4.13% | 15.40% |
| Earnings Yield | -7.94% | 3.15% | 5.25% | 2.15% | 5.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.70 | 2.85 | 2.87 | 3.08 | 3.28 |
| Payables Turnover | 19.53 | 19.62 | 13.06 | 5.69 | 7.90 |
| Inventory Turnover | 0.53 | 0.43 | 0.56 | 0.48 | 0.71 |
| Fixed Asset Turnover | 0.88 | 1.03 | 1.43 | 1.05 | 1.91 |
| Asset Turnover | 0.31 | 0.37 | 0.42 | 0.36 | 0.53 |
| Working Capital Turnover Ratio | 1.92 | 5.37 | 2.17 | 2.13 | 2.58 |
| Cash Conversion Cycle | 805.50 | 964.94 | 756.72 | 814.64 | 575.84 |
| Days of Sales Outstanding | 135.04 | 128.21 | 127.15 | 118.36 | 111.36 |
| Days of Inventory Outstanding | 689.14 | 855.34 | 657.53 | 760.48 | 510.67 |
| Days of Payables Outstanding | 18.69 | 18.61 | 27.96 | 64.20 | 46.20 |
| Operating Cycle | 824.18 | 983.55 | 784.68 | 878.84 | 622.03 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -44.30 | -1.11 | 74.62 | -44.25 | 75.08 |
| Free Cash Flow Per Share | -124.16 | -94.82 | 57.83 | -113.11 | -16.52 |
| Dividend Paid and CapEx Coverage Ratio | -0.44 | -0.01 | 2.03 | -0.49 | 0.69 |
| Capital Expenditure Coverage Ratio | -0.55 | -0.01 | 4.44 | -0.64 | 0.82 |
| Operating Cash Flow Coverage Ratio | -0.14 | -0.00 | 0.40 | -0.24 | 0.51 |
| Operating Cash Flow to Sales Ratio | -0.17 | -0.00 | 0.22 | -0.16 | 0.18 |
| Free Cash Flow Yield | -25.65% | -16.69% | 6.88% | -8.00% | -0.73% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.59 | 31.80 | 19.03 | 46.57 | 19.25 |
| Price-to-Sales (P/S) Ratio | 1.81 | 1.72 | 2.45 | 5.11 | 5.47 |
| Price-to-Book (P/B) Ratio | 1.27 | 1.48 | 1.87 | 3.37 | 5.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.90 | -5.99 | 14.52 | -12.49 | -136.61 |
| Price-to-Operating Cash Flow Ratio | -10.92 | -513.06 | 11.26 | -31.94 | 30.06 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | -0.22 | 0.42 | -0.63 | 0.17 |
| Enterprise Value Multiple | -29.47 | 17.66 | 10.39 | 24.84 | 12.46 |
| Enterprise Value | 85.02B | 109.15B | 109.37B | 185.17B | 266.60B |
| EV to EBITDA | -29.47 | 17.66 | 10.39 | 24.84 | 12.46 |
| EV to Sales | 2.57 | 2.71 | 2.55 | 5.39 | 5.22 |
| EV to Free Cash Flow | -5.53 | -9.44 | 15.15 | -13.17 | -130.43 |
| EV to Operating Cash Flow | -15.50 | -808.50 | 11.74 | -33.67 | 28.70 |
| Tangible Book Value Per Share | 359.19 | 367.10 | 424.54 | 392.25 | 388.99 |
| Shareholders’ Equity Per Share | 379.91 | 384.95 | 450.18 | 419.61 | 411.26 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.27 | 0.32 | 0.24 | 0.30 | 0.25 |
| Revenue Per Share | 267.09 | 330.64 | 343.54 | 276.27 | 412.88 |
| Net Income Per Share | -38.43 | 17.87 | 44.13 | 30.34 | 117.26 |
| Tax Burden | 0.74 | 0.68 | 0.76 | 0.70 | 0.75 |
| Interest Burden | 1.02 | 0.89 | 0.99 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.47 | 0.42 | 0.26 | 0.26 | 0.14 |
| SG&A to Revenue | 0.39 | 0.32 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Income Quality | 1.15 | -0.06 | 1.69 | -1.02 | 0.48 |
Currency in JPY
